Syncore Biotechnology Pancreatic Cancer Treatment Patent EP3565530A1

The EPO has published patent application EP3565530A1 by Syncore Biotechnology Co., Ltd. covering compositions and methods for treating refractory or multidrug resistant pancreatic cancer using combinations of therapeutic agents including A61K 31/337 (likely paclitaxel or analogs) and A61K 31/7068 (likely gemcitabine or analogs) in liposomal formulations (A61K 9/127). The A61P 35/00 classification confirms the anticancer therapeutic use. This publication establishes prior art status and applies to all 38 designated European Contracting States. Competitors developing pancreatic cancer treatments should review the published claims for potential freedom-to-operate concerns. The patent application is now publicly available and will proceed to examination.